{"id":"corticoids-plus-n-acetyl-cysteine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Immunosuppression/infection risk"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL600","moleculeType":"Small molecule","molecularWeight":"163.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Corticosteroids suppress inflammatory and immune responses by inhibiting cytokine production and immune cell activation. N-acetyl cysteine (NAC) acts as a mucolytic agent and antioxidant, replenishing glutathione stores and reducing oxidative stress in respiratory tissue. The combination aims to address both inflammatory and oxidative components of acute lung injury or respiratory disease.","oneSentence":"Corticoids reduce inflammation and immune response while N-acetyl cysteine provides antioxidant support and mucolytic activity to protect lung tissue.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:40.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute respiratory distress syndrome (ARDS) or severe respiratory inflammation (Phase 3 trial context suggests acute lung injury)"}]},"trialDetails":[{"nctId":"NCT05986318","phase":"PHASE2","title":"Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease","status":"RECRUITING","sponsor":"David Palma","startDate":"2025-01-07","conditions":"Lung Cancer, Interstitial Lung Disease","enrollment":98},{"nctId":"NCT06956482","phase":"PHASE3","title":"PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2026-02","conditions":"Alcoholic Hepatitis","enrollment":477},{"nctId":"NCT05294744","phase":"NA","title":"Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)","status":"RECRUITING","sponsor":"Bioaraba Health Research Institute","startDate":"2022-10-07","conditions":"Alcoholic Hepatitis","enrollment":390},{"nctId":"NCT00863785","phase":"PHASE3","title":"Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2004-04","conditions":"Alcoholic Hepatitis","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AAH-NAC study"],"phase":"phase_3","status":"active","brandName":"Corticoids plus N Acetyl Cysteine","genericName":"Corticoids plus N Acetyl Cysteine","companyName":"Centre Hospitalier Universitaire, Amiens","companyId":"centre-hospitalier-universitaire-amiens","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Corticosteroids, such as prednisolone, and N-Acetylcysteine (NAC) are being studied together in clinical trials for conditions including severe alcoholic hepatitis. The exact mechanism of action is not specified, but NAC is known to be involved in antioxidant processes, as indicated by its entry in ChEMBL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}